JP2016528231A5 - - Google Patents

Download PDF

Info

Publication number
JP2016528231A5
JP2016528231A5 JP2016531836A JP2016531836A JP2016528231A5 JP 2016528231 A5 JP2016528231 A5 JP 2016528231A5 JP 2016531836 A JP2016531836 A JP 2016531836A JP 2016531836 A JP2016531836 A JP 2016531836A JP 2016528231 A5 JP2016528231 A5 JP 2016528231A5
Authority
JP
Japan
Prior art keywords
cgrp
related peptide
calcitonin gene
seq
cys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016531836A
Other languages
English (en)
Japanese (ja)
Other versions
JP6538682B2 (ja
JP2016528231A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/048724 external-priority patent/WO2015017455A1/en
Publication of JP2016528231A publication Critical patent/JP2016528231A/ja
Publication of JP2016528231A5 publication Critical patent/JP2016528231A5/ja
Application granted granted Critical
Publication of JP6538682B2 publication Critical patent/JP6538682B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016531836A 2013-07-30 2014-07-29 Ｃｇｒｐアゴニストペプチド Active JP6538682B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361860244P 2013-07-30 2013-07-30
US61/860,244 2013-07-30
PCT/US2014/048724 WO2015017455A1 (en) 2013-07-30 2014-07-29 Cgrp agonist peptides

Publications (3)

Publication Number Publication Date
JP2016528231A JP2016528231A (ja) 2016-09-15
JP2016528231A5 true JP2016528231A5 (enExample) 2017-09-07
JP6538682B2 JP6538682B2 (ja) 2019-07-03

Family

ID=51355665

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016531836A Active JP6538682B2 (ja) 2013-07-30 2014-07-29 Ｃｇｒｐアゴニストペプチド

Country Status (4)

Country Link
US (1) US9951115B2 (enExample)
EP (1) EP3027644B1 (enExample)
JP (1) JP6538682B2 (enExample)
WO (1) WO2015017455A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016183479A1 (en) * 2015-05-13 2016-11-17 The Board Of Regents Of The University Of Oklahoma Variants of adrenomedullin and calcitonin gene-related peptide and methods of use
EP3366286A1 (en) * 2017-02-22 2018-08-29 Johannes Keller Compounds for treating sepsis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021665A1 (en) * 1993-03-24 1994-09-29 Amylin Pharmaceuticals, Inc. Cloned receptors and methods for screening
JP2008500281A (ja) 2004-02-11 2008-01-10 アミリン・ファーマシューティカルズ，インコーポレイテッド アミリンファミリーペプチドおよびそれらを作成し使用するための方法
ES2325773T5 (es) 2004-11-01 2014-02-24 Amylin Pharmaceuticals, Llc. Tratamiento de la obesidad y de los trastornos relacionados
DK1888094T3 (da) 2005-03-31 2009-11-09 Amylin Pharmaceuticals Inc Amylin og amylinagonister til behandling af psykiatriske sygdomme og forstyrrelser
WO2007055743A2 (en) * 2005-11-01 2007-05-18 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
BRPI0722276A2 (pt) * 2007-11-14 2014-04-22 Amylin Pharmaceuticals Inc Métodos para tratar obesidade e doenças e distúrbios relacionados à obesidade
WO2010107874A2 (en) 2009-03-17 2010-09-23 Amylin Pharmaceuticals, Inc. Methods for affecting body composition using amylin agonists
WO2013059336A1 (en) 2011-10-18 2013-04-25 Amylin Pharmaceuticals, Llc Amylin-calcitonin chimeric peptides conjugated to duration enchancing moieties
ES2819825T3 (es) 2012-01-26 2021-04-19 Soares Christopher J Antagonistas peptídicos de la familia calcitonina CGRP de hormonas peptídicas y su uso

Similar Documents

Publication Publication Date Title
HRP20140616T1 (hr) Peptidni analog oksintomodulina
RU2017119773A (ru) Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение
NZ771547A (en) Gip and glp-1 co-agonist compounds
PE20220938A1 (es) Compuestos agonistas de gipr
JP2015513318A5 (enExample)
JP2013515057A5 (enExample)
JP2018135346A5 (enExample)
Ramos-Álvarez et al. A structure–function study of PACAP using conformationally restricted analogs: Identification of PAC1 receptor-selective PACAP agonists
HRP20190689T1 (hr) Muteini suznog lipokalina koji vežu il-4r alfa
JP2018515088A5 (enExample)
NZ593833A (en) Extended recombinant polypeptides and compositions comprising same
WO2019215063A8 (en) Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
BRPI0812795C1 (pt) domínio variável único de imunoglobulina, antagonista tipo 1 do receptor tnfalfa, uso de um domínio ou antagonista de tnfr1, ácido nucleico recombinante, vetor, célula hospedeira, e, composição farmacêutica
JP2019533722A5 (enExample)
EA201170337A1 (ru) Стабильная твердая композиция полипептидного агониста gc-c рецептора, приемлемая для перорального введения
EA201590525A1 (ru) Слитые белки для лечения метаболического синдрома
JP2015517488A5 (enExample)
JP2013543499A5 (enExample)
JP2012115277A5 (enExample)
HRP20150664T1 (hr) Antikancerogeni fuzijski protein
WO2011038900A3 (en) Peptide analogues of glucagon for diabetes therapy
JP2017221201A5 (enExample)
HRP20191965T1 (hr) Stabilizirani polipeptidi faktora rasta slični inzulinu
JP2014529399A5 (enExample)
WO2012174397A3 (en) Anti-inflammatory pharmaceutical products